Project Details Analogue-based Drug Discovery Vol. III

Project No.:
2011-011-1-700
Start Date:
01 June 2011
End Date:
01 March 2013
Division Name:
Chemistry and Human Health Division
Division No.:
700

Objective

The project “Analogue-based Drug Discovery II” has been successfully completed within two years and the second volume of the book series has been published by Wiley-VCH. The good resonance of both Vol. I and Vol. II justifies a continuation of the book series with a third volume to be published in 2012.

Description

proposed content:

General Aspects

Lead and Drug Optimizations
(Fischer, Richter, Hungary)

Physicochemical Parameters
(Ulander, AstraZeneca, Sweden)

Metabolic Stability and Optimization of Drug Analogues
(Vastag, Richter, Hungary)

Process Chemistry Driven Synthesis of New Analogues
(Chorghade, IUPAC)

Drug Classes

Epigenetic Drugs
(Ganesan, University of East Anglia, Norwick, UK)

P2Y12 Receptor Inhibitors
(Jakubowski, Lilly, USA)

SERM Drugs
(Erhardt, Uni. of Toledo, USA)

Insulin Analogues
(Sridhar, Endocrine and Diabetes Centre, India)

Case Studies

Dabigatran
(Priebke, Boehringer Ingelheim, Germany)

Escitalopram
(Bøgesø, Lundbeck, Denmark)

Tapentadol
(Buschmann, Grünenthal, Germany)

Ulimorelin
(Peterson, Tranzyme, USA)

Asenapine
(Gilfillan, Merck, USA)

Cabazitaxel
(Vrignaud, Bouchard, Sanofi Aventis, France)

Boceprevir
(Prongay, Venkatraman; Merck, USA)

Progress

Project completed – the book edited by Janos Fischer, C. Robin Ganellin, and David P. Rotella has been published by Wiley-VCH, 2013, ISBN: 978-3-527-33073-7

A overview is published in Chem Int Jan 2013

Last update 15 April 2013